News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Numerate and Intellikine, Inc. Conclude Research Collaboration to Discover Selective Inhibitors Against PI3 Kinase Alpha


8/11/2010 9:03:33 AM

SAN BRUNO & LA JOLLA, Calif.--(BUSINESS WIRE)--Numerate, Inc. and Intellikine, Inc. today announced the successful conclusion of their research collaboration to discover novel small molecule compounds targeting the PI3K/mTOR signaling pathway. The collaboration combined Intellikine’s unique capabilities in x-ray crystal structure-guided medicinal chemistry and drug discovery with Numerate’s powerful computational drug design platform to identify potent, selective and drug-like inhibitors of PI3 kinase alpha, an important target in cancer therapy.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES